Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
GKOS | US
2.51
1.95%
Healthcare
Medical Instruments & Supplies
30/06/2024
04/10/2024
130.98
128.86
131.64
128.48
Glaukos Corporation an ophthalmic medical technology and pharmaceutical company focuses on the development of novel therapies for the treatment of glaucoma corneal disorders and retinal diseases. It offers iStent iStent inject iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite an implantable device intended to reduce the intraocular pressure of the eye; and iDose TR a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo California.
View LessPositive Momentum
Low 6-Month Volatility (<30%)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
25.0%1 month
32.0%3 months
31.0%6 months
28.9%-
-
10.60
0.24
0.17
-57.89
20.32
1.64
-84.56M
7.20B
7.20B
-
-28.71
1.90K
19.00
-27.49
5.30
7.37
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
7.38
Range1M
14.03
Range3M
29.39
Rel. volume
0.73
Price X volume
52.11M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Penumbra Inc | PEN | Medical Devices | 194.73 | 7.56B | 0.89% | 563.38 | 19.70% |
Masimo Corporation | MASI | Medical Instruments & Supplies | 138.83 | 7.42B | 2.43% | 90.61 | 63.08% |
BLCO | BLCO | Medical Instruments & Supplies | 19 | 6.69B | -0.31% | n/a | 71.22% |
Lyxor Stoxx Europe 600 Ins ETF Acc A/I | INSP | Medical Devices | 214.93 | 6.41B | 1.33% | 1.01K | 3.84% |
Merit Medical Systems Inc | MMSI | Medical Instruments & Supplies | 95.63 | 5.57B | -1.02% | 48.60 | 67.92% |
Stevanato Group S.p.A. | STVN | Medical Instruments & Supplies | 18.97 | 5.18B | -5.15% | 41.82 | 23.86% |
DENTSPLY SIRONA Inc | XRAY | Medical Instruments & Supplies | 25.22 | 5.11B | 0.88% | n/a | 72.19% |
ICU Medical Inc | ICUI | Medical Instruments & Supplies | 179.2 | 4.38B | -0.65% | n/a | 82.41% |
Integer Holdings Corporation | ITGR | Medical Devices | 129.11 | 4.33B | 1.48% | 41.14 | 78.04% |
Haemonetics Corporation | HAE | Medical Instruments & Supplies | 77.89 | 3.99B | -1.79% | 35.78 | 135.15% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
The AZEK Company Inc | AZEK | Building Products & Equipment | 43.79 | 6.32B | -5.75% | 41.03 | 49.22% |
VeriFone Systems Inc | PAY | Building Products & Equipment | 20.8 | 2.59B | 4.58% | 76.96 | 2.10% |
HNI Corporation | HNI | Building Products & Equipment | 53.27 | 2.51B | 0.72% | 21.28 | 76.47% |
Tootsie Roll Industries Inc | TR | Confectioners | 29.71 | 2.17B | 1.40% | 23.62 | 1.84% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -57.89 | 7.69 | Cheaper |
Ent. to Revenue | 20.32 | 64.13 | Cheaper |
PE Ratio | - | 50.95 | - |
Price to Book | 10.60 | 6.11 | Expensive |
Dividend Yield | - | 1.34 | - |
Std. Deviation (3M) | 30.97 | 55.82 | Lower Risk |
Debt to Equity | 0.24 | 0.86 | Cheaper |
Debt to Assets | 0.17 | 0.26 | Cheaper |
Market Cap | 7.20B | 9.95B | Emerging |